NUVBNYSEPharmaceutical PreparationsFiscal year ends December 31
Nuvation Bio Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$4.48+0.03 (+0.67%)
Close on Oct 19, 2026
- Market cap
- $1.56M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
66.5%
233M of 351M shares
Institutional holders
244
40 new, 25 sold out
Net institutional buying
14M
In Q2 2026
Insider trades, 12 months
1 buys · 17 sales
Net sold $9.56M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| David Hung, M.D | 61,269,498 | 27.70% | 13D (active) amendment | Mar 24, 2024 |
| FMR LLC | 50,599,225 | 15.00% | 13G (passive) amendment | Mar 31, 2025 |
| Abigail P. Johnson | 45,285,572 | 13.50% | 13G (passive) amendment | Dec 31, 2024 |
| Xiangmin Cui | 26,600,496 | 8.00% | 13D (active) | Sep 3, 2024 |
| BlackRock, Inc. | 21,708,843 | 6.40% | 13G (passive) | Jun 30, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of NUVB | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| FMR LLC | 52,230,295 | 14.88% | $296.67M | +240,702 | 0.01% |
| BlackRock, Inc. | 27,630,837 | 7.87% | $156.94M | +2,530,463 | 0.00% |
| Decheng Capital LLC | 25,954,439 | 7.39% | $147.42M | – | 20.15% |
| Vanguard Capital Management LLC | 11,919,514 | 3.39% | $67.70M | +293,316 | 0.00% |
| Omega Fund Management, LLC | 8,081,089 | 2.30% | $45.90M | – | 24.72% |
| Laurion Capital Management LP | 7,820,013 | 2.23% | $44.42M | −2,625 | 1.14% |
| State Street Corp | 7,370,794 | 2.10% | $41.87M | +585,867 | 0.00% |
| Geode Capital Management, LLC | 6,244,805 | 1.78% | $35.48M | +381,151 | 0.00% |
| Duquesne Family Office LLC | 4,539,800 | 1.29% | $25.79K | – | 0.49% |
| American Century Companies Inc | 4,499,643 | 1.28% | $25.56M | +1,602,565 | 0.01% |
| Bank Of America Corp /De/ | 3,529,748 | 1.01% | $20.05M | +309,922 | 0.00% |
| Tang Capital Management LLC | 3,299,557 | 0.94% | $18.74M | +150,000 | 0.85% |
| Redmile Group, LLC | 3,031,009 | 0.86% | $17.22M | −122,247 | 1.16% |
| Vanguard Portfolio Management LLC | 2,688,666 | 0.77% | $15.27M | +413,220 | 0.00% |
| Aqr Capital Management LLC | 2,356,429 | 0.67% | $13.38M | +360,671 | 0.00% |
| Northern Trust Corp | 2,321,873 | 0.66% | $13.19M | +318,765 | 0.00% |
| Algert Global LLC | 2,277,358 | 0.65% | $12.94M | +435,280 | 0.15% |
| Hrt Financial LP | 2,207,779 | 0.63% | $12.54K | New | 0.00% |
| Charles Schwab Investment Management Inc | 2,058,870 | 0.59% | $11.69M | +66,419 | 0.00% |
| Dimensional Fund Advisors LP | 2,047,876 | 0.58% | $11.63M | −4,815 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 244 | 233M | 66.5% | 40 / 111 | 52 / 25 | 24M | 10M |
| Q1 2026 | 233 | 221M | 62.8% | 48 / 91 | 59 / 37 | 46M | 21M |
| Q4 2025 | 224 | 212M | 60.3% | 56 / 72 | 70 / 33 | 24M | 34M |
| Q3 2025 | 203 | 221M | 63.0% | 40 / 83 | 48 / 17 | 22M | 26M |
| Q2 2025 | 182 | 225M | 64.1% | 43 / 79 | 31 / 20 | 27M | 10M |
| Q1 2025 | 161 | 207M | 59.1% | 23 / 54 | 52 / 19 | 21M | 9M |
| Q4 2024 | 160 | 198M | 56.3% | 29 / 64 | 36 / 22 | 41M | 29M |
| Q3 2024 | 154 | 188M | 53.4% | 26 / 60 | 36 / 18 | 59M | 8M |
| Q2 2024 | 148 | 153M | 43.6% | 42 / 46 | 39 / 17 | 27M | 11M |
| Q1 2024 | 124 | 137M | 39.0% | 27 / 42 | 38 / 17 | 13M | 11M |
| Q4 2023 | 116 | 135M | 38.5% | 14 / 44 | 32 / 23 | 18M | 19M |
| Q3 2023 | 125 | 137M | 39.0% | 13 / 50 | 36 / 12 | 10M | 12M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of NUVB | Value | % of fund | As of |
|---|---|---|---|---|---|
| Fidelity Growth Company Fund | 17,536,601 | 4.99% | $83.82M | 0.08% | May 31, 2026 |
| Vanguard Total Stock Market Index Fund | 8,849,329 | 2.52% | $50.26M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 6,570,059 | 1.87% | $37.32M | 0.04% | Jun 30, 2026 |
| Fidelity Growth Company K6 Fund | 4,910,563 | 1.40% | $23.47M | 0.09% | May 31, 2026 |
| Fidelity Series Growth Company Fund | 4,516,478 | 1.29% | $21.59M | 0.09% | May 31, 2026 |
| Small Cap Growth Fund | 3,423,823 | 0.98% | $21.67M | 0.39% | Jul 31, 2026 |
| Vanguard Extended Market Index Fund | 2,787,909 | 0.79% | $15.84M | 0.02% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 2,755,576 | 0.78% | $17.44M | 0.05% | Jul 31, 2026 |
| iShares Russell 2000 Growth ETF | 2,326,568 | 0.66% | $13.21M | 0.09% | Jun 30, 2026 |
| Select Biotechnology Portfolio | 1,758,533 | 0.50% | $8.41M | 0.16% | May 31, 2026 |
| iShares Biotechnology ETF | 1,743,392 | 0.50% | $9.90M | 0.11% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P(R) Pharmaceuticals ETF | 1,427,463 | 0.41% | $8.11M | 1.89% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 1,239,034 | 0.35% | $5.92M | 0.01% | May 31, 2026 |
| Vanguard Russell 2000 Index Fund | 1,238,081 | 0.35% | $5.92M | 0.03% | May 31, 2026 |
| Schwab U.S. Small-Cap ETF | 1,145,077 | 0.33% | $5.47M | 0.02% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| David Hung | PRESIDENT AND CEO, Director, 10% owner | 60,281,054 | 17.17% | Mar 3, 2026 |
| Junyuan Jerry Wang | CEO, ANHEART THERAPEUTICS LTD., Director | 6,112,686 | 1.74% | Nov 13, 2024 |
| Gary Hattersley | CHIEF SCIENTIFIC OFFICER | 0 | – | Aug 21, 2026 |
| Philippe Sauvage | Chief Financial Officer | 54,130 | 0.02% | Jul 17, 2026 |
| Stacy Markel | CHIEF PEOPLE OFFICER | 157,591 | 0.04% | Jun 24, 2026 |
| Kerry Wentworth | CHIEF REGULATORY OFFICER | 116,000 | 0.03% | Jun 24, 2026 |
| Dongfang Liu | CHIEF MEDICAL OFFICER | 68,000 | 0.02% | Apr 21, 2026 |
| Colleen Sjogren | Chief Commercial Officer | 84,000 | 0.02% | Mar 3, 2026 |
| David C. Hanley | CHIEF TECHNICAL OPERATIONS | 24,000 | 0.01% | Mar 3, 2026 |
| Moses Makunje | SEE REMARKS | 68,137 | 0.02% | Mar 3, 2026 |
| Robert Mashal | Director | 225,000 | 0.06% | Jun 11, 2026 |
| W. Anthony Vernon | Director | 254,100 | 0.07% | May 26, 2026 |
| Robert B. Bazemore | Director | 5,000 | 0.00% | May 26, 2026 |
| Kathryn E. Falberg | Director | 250,000 | 0.07% | May 26, 2026 |
| Kim D. Blickenstaff | Director | 172,189 | 0.05% | May 26, 2026 |
| Xiangmin Cui | Director | 25,954,439 | 7.39% | May 26, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Gary Hattersley CHIEF SCIENTIFIC OFFICER | Aug 19, 2026 | Sale(10b5-1 plan) | −100,000 | $7.09 | $709.00K | 0 |
| Gary Hattersley CHIEF SCIENTIFIC OFFICER | Aug 19, 2026 | Option exercise | +100,000 | $1.87 | $187.00K | 100,000 |
| Philippe Sauvage Chief Financial Officer | Jul 15, 2026 | Option exercise | +39,999 | $2.17 | $86.80K | 54,130 |
| Philippe Sauvage Chief Financial Officer | Jul 15, 2026 | Option exercise | +1 | $1.97 | $2 | 54,131 |
| Kerry Wentworth CHIEF REGULATORY OFFICER | Jun 23, 2026 | Option exercise | +63,000 | $2.93 | $184.59K | 116,000 |
| Kerry Wentworth CHIEF REGULATORY OFFICER | Jun 23, 2026 | Sale(10b5-1 plan) | −63,000 | $6.02 | $379.26K | 53,000 |
| Stacy Markel CHIEF PEOPLE OFFICER | Jun 23, 2026 | Option exercise | +34,620 | $1.74 | $60.24K | 157,591 |
| Stacy Markel CHIEF PEOPLE OFFICER | Jun 23, 2026 | Sale(10b5-1 plan) | −125,000 | $6.03 | $753.75K | 32,591 |
| Stacy Markel CHIEF PEOPLE OFFICER | Jun 23, 2026 | Option exercise | +90,380 | $1.87 | $169.01K | 122,971 |
| Philippe Sauvage Chief Financial Officer | Jun 23, 2026 | Sale(10b5-1 plan) | −47,668 | $6.01 | $286.48K | 12,673 |
| Philippe Sauvage Chief Financial Officer | Jun 23, 2026 | Option exercise | +47,668 | $2.17 | $103.44K | 60,341 |
| Robert Mashal Director | Jun 9, 2026 | Buy | +25,000 | $4.73 | $118.25K | 225,000 |
| Kerry Wentworth CHIEF REGULATORY OFFICER | Apr 17, 2026 | Sale(10b5-1 plan) | −36,750 | $5.01 | $184.12K | 53,000 |
| Kerry Wentworth CHIEF REGULATORY OFFICER | Apr 17, 2026 | Option exercise | +36,750 | $2.93 | $107.68K | 89,750 |
| Dongfang Liu CHIEF MEDICAL OFFICER | Apr 17, 2026 | Option exercise | +50,000 | $1.94 | $97.00K | 68,000 |
| Dongfang Liu CHIEF MEDICAL OFFICER | Apr 17, 2026 | Sale(10b5-1 plan) | −50,000 | $5.02 | $251.00K | 18,000 |
| Kerry Wentworth CHIEF REGULATORY OFFICER | Apr 6, 2026 | Option exercise | +100,000 | $1.87 | $187.00K | 153,000 |
| Kerry Wentworth CHIEF REGULATORY OFFICER | Apr 6, 2026 | Option exercise | +100,000 | $1.94 | $194.00K | 253,000 |
| Kerry Wentworth CHIEF REGULATORY OFFICER | Apr 6, 2026 | Sale(10b5-1 plan) | −200,000 | $4.52 | $904.00K | 53,000 |
| Moses Makunje SEE REMARKS | Feb 27, 2026 | Award | +50,761 | – | – | 68,137 |
| Dongfang Liu CHIEF MEDICAL OFFICER | Dec 1, 2025 | Sale | −150,000 | $7.82 | $1.17M | 18,000 |
| Dongfang Liu CHIEF MEDICAL OFFICER | Dec 1, 2025 | Option exercise | +150,000 | $2.93 | $439.50K | 168,000 |
| Dongfang Liu CHIEF MEDICAL OFFICER | Nov 26, 2025 | Option exercise | +10,000 | $3.61 | $36.10K | 28,000 |
| Dongfang Liu CHIEF MEDICAL OFFICER | Nov 26, 2025 | Sale | −10,000 | $8.00 | $80.00K | 18,000 |
| Dongfang Liu CHIEF MEDICAL OFFICER | Nov 25, 2025 | Option exercise | +10,000 | $3.61 | $36.10K | 28,000 |
| Dongfang Liu CHIEF MEDICAL OFFICER | Nov 25, 2025 | Sale | −10,000 | $7.50 | $75.00K | 18,000 |
| Dongfang Liu CHIEF MEDICAL OFFICER | Nov 20, 2025 | Sale | −20,000 | $7.00 | $140.00K | 18,000 |
| Dongfang Liu CHIEF MEDICAL OFFICER | Nov 20, 2025 | Option exercise | +20,000 | $1.87 | $37.40K | 38,000 |
| Gary Hattersley CHIEF SCIENTIFIC OFFICER | Nov 20, 2025 | Sale | −300,000 | $7.23 | $2.17M | 0 |
| Gary Hattersley CHIEF SCIENTIFIC OFFICER | Nov 20, 2025 | Option exercise | +300,000 | $1.94 | $582.00K | 300,000 |
| Gary Hattersley CHIEF SCIENTIFIC OFFICER | Nov 20, 2025 | Sale | −69,051 | $7.23 | $499.24K | 0 |
| Gary Hattersley CHIEF SCIENTIFIC OFFICER | Nov 20, 2025 | Option exercise | +69,051 | $1.74 | $120.15K | 69,051 |
| David C. Hanley CHIEF TECHNICAL OPERATIONS | Nov 19, 2025 | Sale | −200,000 | $7.14 | $1.43M | 24,000 |
| David C. Hanley CHIEF TECHNICAL OPERATIONS | Nov 19, 2025 | Option exercise | +200,000 | $1.87 | $374.00K | 224,000 |
| Dongfang Liu CHIEF MEDICAL OFFICER | Nov 19, 2025 | Sale | −15,000 | $5.10 | $76.50K | 18,000 |
| Dongfang Liu CHIEF MEDICAL OFFICER | Nov 19, 2025 | Option exercise | +15,000 | $1.87 | $28.05K | 30,000 |
| Dongfang Liu CHIEF MEDICAL OFFICER | Nov 17, 2025 | Sale | −15,000 | $4.77 | $71.55K | 15,000 |
| Dongfang Liu CHIEF MEDICAL OFFICER | Nov 17, 2025 | Option exercise | +15,000 | $1.87 | $28.05K | 30,000 |
| Gary Hattersley CHIEF SCIENTIFIC OFFICER | Oct 27, 2025 | Option exercise | +100,000 | $1.74 | $174.00K | 100,000 |
| Gary Hattersley CHIEF SCIENTIFIC OFFICER | Oct 27, 2025 | Sale(10b5-1 plan) | −100,000 | $5.02 | $502.00K | 0 |
| Stacy Markel CHIEF PEOPLE OFFICER | Jun 18, 2025 | Buy | +10,000 | $1.71 | $17.10K | 29,591 |
| Philippe Sauvage Chief Financial Officer | Jun 17, 2025 | Buy | +4,000 | $1.79 | $7.16K | 9,902 |
| Philippe Sauvage Chief Financial Officer | Jun 16, 2025 | Buy | +3,300 | $1.84 | $6.07K | 5,902 |
| David Hung PRESIDENT AND CEO, Director, 10% owner | Jun 16, 2025 | Buy | +500,000 | $1.79 | $895.00K | 59,281,054 |
| Colleen Sjogren Chief Commercial Officer | Jun 16, 2025 | Buy | +50,000 | $1.81 | $90.50K | 81,000 |
| Kerry Wentworth CHIEF REGULATORY OFFICER | Jun 16, 2025 | Buy | +26,000 | $1.79 | $46.54K | 26,000 |
| Kerry Wentworth CHIEF REGULATORY OFFICER | Jun 16, 2025 | Buy | +24,000 | $1.80 | $43.20K | 50,000 |
| Dongfang Liu CHIEF MEDICAL OFFICER | May 2, 2025 | Option exercise | +20,000 | $1.94 | $38.80K | 32,000 |
| Dongfang Liu CHIEF MEDICAL OFFICER | May 2, 2025 | Sale(10b5-1 plan) | −20,000 | $2.50 | $50.00K | 12,000 |
| David Hung PRESIDENT AND CEO, Director, 10% owner | Apr 7, 2025 | Buy | +300,000 | $1.63 | $489.00K | 58,781,054 |
| David Hung PRESIDENT AND CEO, Director, 10% owner | Apr 4, 2025 | Buy | +200,000 | $1.66 | $332.00K | 58,481,054 |
| Robert Mashal Director | Apr 1, 2025 | Buy | +1,100 | $1.67 | $1.84K | 101,100 |
| Robert Mashal Director | Apr 1, 2025 | Buy | +98,900 | $1.67 | $165.16K | 200,000 |
| Junyuan Jerry Wang CEO, ANHEART THERAPEUTICS LTD., Director | Nov 11, 2024 | Sale | −56,361 | $2.89 | $162.88K | 3,866,228 |
| Robert Mashal Director | Oct 8, 2024 | Buy | +99,981 | $2.20 | $219.96K | 100,000 |
| Robert Mashal Director | Oct 8, 2024 | Buy | +19 | $2.20 | $42 | 19 |
| Xiangmin Cui Director | Sep 4, 2024 | Conversion | +5,157,900 | – | – | 7,611,031 |
| Xiangmin Cui Director | Sep 4, 2024 | Conversion | +967,100 | – | – | 1,281,206 |
| Xiangmin Cui Director | Sep 4, 2024 | Conversion | +12,879,200 | – | – | 17,062,202 |
| Junyuan Jerry Wang CEO, ANHEART THERAPEUTICS LTD., Director | Sep 4, 2024 | Conversion | +2,543,600 | – | – | 3,922,589 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Hattersley Gary Officer | Aug 19, 2026 | 100,000 | $696.00K | Aug 19, 2026 | Exercise of Stock Options |
| Markel Stacy Officer | Jun 23, 2026 | 125,000 | $720.00K | Jun 23, 2026 | Exercise of Stock Options |
| Wentworth Kerry Officer | Jun 23, 2026 | 63,000 | $362.88K | Jun 23, 2026 | Exercise of Stock Options |
| Sauvage Philippe Officer | Jun 23, 2026 | 47,668 | $274.57K | Jun 23, 2026 | Exercise of Stock Options |
| Wentworth Kerry Officer | Apr 17, 2026 | 36,750 | $176.77K | Apr 17, 2026 | Exercise of Stock Options |
| Liu Dongfang Officer | Apr 17, 2026 | 50,000 | $240.50K | Apr 17, 2026 | Exercise of Stock Options |
| Wentworth Kerry Officer | Apr 6, 2026 | 200,000 | $882.00K | Apr 6, 2026 | Exercise of Stock Options |
| Liu Dongfang Officer | Dec 1, 2025 | 150,000 | $1.17M | Dec 1, 2025 | Exercise of options under a registered plan |
| Liu Dongfang Officer | Nov 26, 2025 | 10,000 | $80.00K | Nov 26, 2025 | Exercise of options under a registered plan |
| Liu Dongfang Officer | Nov 25, 2025 | 10,000 | $75.00K | Nov 25, 2025 | Exercise of options under a registered plan |
| Liu Dongfang Officer | Nov 20, 2025 | 20,000 | $140.07K | Nov 20, 2025 | Exercise of options under a registered plan |
| Hattersley Gary Officer | Nov 20, 2025 | 369,051 | $2.67M | Nov 20, 2025 | Exercise of options under a registered plan |
| Liu Dongfang Officer | Nov 19, 2025 | 15,000 | $76.55K | Nov 19, 2025 | Exercise of options under a registered plan |
| Hanley David Officer | Nov 19, 2025 | 200,000 | $1.43M | Nov 19, 2025 | Exercise of options under a registered plan |
| Liu Dongfang Officer | Nov 17, 2025 | 15,000 | $71.48K | Nov 17, 2025 | Exercise of options under a registered plan |